[HTML][HTML] Convalescent plasma: new evidence for an old therapeutic tool?
G Marano, S Vaglio, S Pupella, G Facco… - Blood …, 2016 - ncbi.nlm.nih.gov
Passive immunisation for the prevention and treatment of human infectious diseases can be
traced back to the 20 th century. The recent Ebola virus outbreak in West Africa has turned …
traced back to the 20 th century. The recent Ebola virus outbreak in West Africa has turned …
Vaccine-associated enhanced disease and pathogenic human coronaviruses
Vaccine-associated enhanced disease (VAED) is a difficult phenomenon to define and can
be confused with vaccine failure. Using studies on respiratory syncytial virus (RSV) …
be confused with vaccine failure. Using studies on respiratory syncytial virus (RSV) …
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Without an approved vaccine or treatments, Ebola outbreak management has been limited
to palliative care and barrier methods to prevent transmission. These approaches, however …
to palliative care and barrier methods to prevent transmission. These approaches, however …
[HTML][HTML] Late Ebola virus relapse causing meningoencephalitis: a case report
Background There are thousands of survivors of the 2014 Ebola outbreak in west Africa.
Ebola virus can persist in survivors for months in immune-privileged sites; however, viral …
Ebola virus can persist in survivors for months in immune-privileged sites; however, viral …
A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus
The recent Ebola virus (EBOV) epidemic highlighted the need for effective vaccines and
therapeutics to limit and prevent outbreaks. Host antibodies against EBOV are critical for …
therapeutics to limit and prevent outbreaks. Host antibodies against EBOV are critical for …
[HTML][HTML] Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
L Oestereich, A Lüdtke, S Wurr, T Rieger… - Antiviral research, 2014 - Elsevier
Outbreaks of Ebola hemorrhagic fever in sub-Saharan Africa are associated with case
fatality rates of up to 90%. Currently, neither a vaccine nor an effective antiviral treatment is …
fatality rates of up to 90%. Currently, neither a vaccine nor an effective antiviral treatment is …
Nanozyme-strip for rapid local diagnosis of Ebola
D Duan, K Fan, D Zhang, S Tan, M Liang, Y Liu… - Biosensors and …, 2015 - Elsevier
Ebola continues to rage in West Africa. In the absence of an approved vaccine or treatment,
the priority in controlling this epidemic is to promptly identify and isolate infected individuals …
the priority in controlling this epidemic is to promptly identify and isolate infected individuals …
Structure of the Inmazeb cocktail and resistance to Ebola virus escape
Monoclonal antibodies can provide important pre-or post-exposure protection against
infectious disease for those not yet vaccinated or in individuals that fail to mount a protective …
infectious disease for those not yet vaccinated or in individuals that fail to mount a protective …
A serological point-of-care test for the detection of IgG antibodies against Ebola virus in human survivors
Ebola virus disease causes widespread and highly fatal epidemics in human populations.
Today, there is still great need for point-of-care tests for diagnosis, patient management and …
Today, there is still great need for point-of-care tests for diagnosis, patient management and …
[HTML][HTML] Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection
Antibodies are promising post-exposure therapies against emerging viruses, but which
antibody features and in vitro assays best forecast protection are unclear. Our international …
antibody features and in vitro assays best forecast protection are unclear. Our international …